Wolters Kluwer Health Teams up with Amazing Charts/Pri-Med to Enhance Prescription Workflow and Patient Education through EHRs

 

HUDSON, Ohio--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, is expanding its relationship with Amazing Charts, a division of Pri-Med™, to further both organizations’ missions of enhancing prescription workflow and patient education. The new Pri-Med InLight™ electronic health record (EHR) system employs drug data from Wolters Kluwer Clinical Drug Information solution, Medi-Span®, and makes Wolters Kluwer Integrated Patient Education available to all users.

By 2015, both Amazing Charts EHR and Pri-Med InLight EHR will utilize Wolters Kluwer Integrated Patient Education, an easily accessible and searchable library of more than 6,000 patient-facing educational leaflets, available in up to 19 languages and designed to reinforce providers’ advice and help patients better understand and comply with treatments. Integrated Patient Education provides Pri-Med InLight EHR users with materials on adult and pediatric medications, conditions, procedures, natural products, discharge instructions, and healthy living.Wolters Kluwer Health offerings have long powered decision support functionality in Amazing Charts EHR solutions for outpatient primary care and specialists’ practices. After being acquired by Pri-Med in 2012, Amazing Charts chose Wolters Kluwer Clinical Drug Information solutions to help build Pri-Med InLight, a problem-oriented medical record that emphasizes patient education and engagement. Currently in limited release, Pri-Med InLight debuts to the general marketplace in December 2014.

“When patients understand their treatment plans, they’re more likely to adhere to them, and that can reduce time-consuming and costly readmissions and corrective treatments,” stated Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “Wolters Kluwer Integrated Patient Education is designed to increase health literacy and engagement while improving patient outcomes. It aligns perfectly with the themes that guide Amazing Charts: Providing highly usable solutions for clinicians that help create more time for engaging directly with patients and focusing on connecting patients to their care.”

“Amazing Charts and Pri-Med are focused on helping clinicians make better decisions at the point of care,” said Christine Tremblay, Director of Product Strategy, Amazing Charts. “We support this mission by giving our customers the latest information about medications from Wolters Kluwer, so they can make smart choices for their patients. Education handouts reinforce these choices after the office visit because having more information helps increase patient adherence to prescribed medications. When combined with our patient portal for reminders and follow-up, our clinicians can increase patient contact and influence patient behavior.”

About Wolters Kluwer Health

Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®Lexicomp®Lippincott Williams & WilkinsMedicom®Medi-Span®MedknowOvid®Pharmacy OneSource®ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle: @WKHealth.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.